<DOC>
	<DOCNO>NCT02364531</DOCNO>
	<brief_summary>The purpose study temporally evaluate impact abiraterone acetate ( ZYTIGA ) therapy Patient Reported Outcomes ( PROs ) clinical outcome chemotherapy-naive metastatic castrate-resistant prostate cancer ( mCRPC ) population . Safety data , level health care resource utilization associate abiraterone acetate ( ZYTIGA ) therapy also prospectively collect analyze .</brief_summary>
	<brief_title>A Canadian Observational Study Metastatic Cancer Prostate : A Study ZYTIGA Use Community Urology Setting</brief_title>
	<detailed_description>This non-interventional , multicenter ( one hospital medical school team work medical research study ) , prospective ( observation population sufficient number person sufficient number year generate incidence mortality rate subsequent selection study group ) , observational ( clinical study participant may receive diagnostic , therapeutic , types intervention , investigator assign participant specific intervention ) study . This observational study focus chemotherapy-naive metastatic castrate-resistant prostate cancer ( mCRPC ) participant initiate abiraterone acetate ( ZYTIGA ) therapy treatment asymptomatic mildly symptomatic disease . All treatment decision make discretion Investigator per clinical practice accordance approve local Product Monograph treatment algorithm . The plan study duration three year initial first participant enrolment . Participants follow maximum 72 week time initiation abiraterone acetate ( ZYTIGA ) treatment , time early study withdrawal/termination . Data collect paper-based electronic data capture ( eDC ) primarily collect PROs clinical outcome . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Participants must confirm diagnosis metastatic castrateresistant prostate cancer ( mCRPC ) accord medical history rise ProstateSpecific Antigen ( PSA ) level radiographic progression ( document previous positive bone scan metastatic lesion identify CT MRI ) despite ongoing conventional Androgen deprivation therapy ( ADT ) Participant ( legally accept representative ) must able sign inform consent form ( ICF ) indicate understand procedure data collection willing participate study Participant must able understand complete study questionnaires Abiraterone Acetate ( ZYTIGA ) choose treatment mCRPC disease progression part standard care Male participant age great ( &gt; ) 18 year Participants currently participate another investigational clinical study ZYTIGA investigational drug Participants receive prior cytotoxic chemotherapy prostate cancer receive ADT Participants condition , opinion investigator , may affect participant health outcome trial ( i.e . uncontrolled disease ) Life expectancy le ( &lt; ) 1 year History another malignancy within previous 5 year curatively treat nonmelanoma skin cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Prostatic Neoplasms</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Observational</keyword>
	<keyword>Abiraterone Acetate</keyword>
	<keyword>ZYTIGA</keyword>
</DOC>